Disease Domain | Count |
---|---|
Nervous System Diseases | 17 |
Endocrinology and Metabolic Disease | 6 |
Neoplasms | 2 |
Top 5 Drug Type | Count |
---|---|
Small molecule drug | 12 |
AAV based gene therapy | 4 |
Unknown | 2 |
ASO | 1 |
Gene therapy | 1 |
Target |
Mechanism eNOS modulators |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication |
Drug Highest PhaseApproved |
First Approval Ctry. / Loc. European Union [+3] |
First Approval Date19 Jun 2025 |
Target |
Mechanism Dystroglycan stimulants |
Active Org. |
Originator Org. |
Active Indication |
Drug Highest PhaseApproved |
First Approval Ctry. / Loc. European Union [+3] |
First Approval Date31 Jul 2014 |
Start Date14 May 2024 |
Sponsor / Collaborator |
Start Date04 Mar 2024 |
Sponsor / Collaborator |
Start Date31 Jan 2024 |
Sponsor / Collaborator |
Drug(Targets) | Indications | Global Highest Phase |
---|---|---|
Ataluren ( DAG1 ) | Muscular Dystrophy, Duchenne More | Approved |
Sepiapterin ( eNOS ) | Phenylketonurias More | Approved |
Eladocagene exuparvovec ( DDC ) | Aromatic Amino Acid Decarboxylase Deficiency More | Approved |
Vatiquinone ( 12/15-LOX ) | Friedreich Ataxia More | Phase 3 |
Votoplam ( HTT x splicing factor ) | Huntington Disease More | Phase 2 |